September Tips
September is a strange month, isn't it? It's the unofficial end of summer, so we're all getting back into the swing with everyone back in the office. Yet…
September is a strange month, isn't it? It's the unofficial end of summer, so we're all getting back into the swing with everyone back in the office. Yet…
At Lacerta Bio, we believe that business development is a process...a process with discrete steps, activities, timeframes, and deliverables. Yet many companies, fully aware of how to run…
Texas-based Pernix Therapeutics announced a $30 million divestment of a portfolio of generic assets to Breckenridge: Under the terms of the agreement, Breckenridge will pay…
We don't normally comment on stock activity, but the market response to the Perrigo Elan announcement caught our eye: As was pointed out in The Guardian: Perrigo, which…
Just sign a piece a paper and drive off with a new car. They sure make it sound east, don't they? Yet VW does have a good point.…
As we bring 2012 to a close, we're looking back at a few of the interesting events that took place. It was a challenge to whittle this down to a…
While we were recovering from our turkey-induced slumbers, we read the shocking news that Michael Porter's Monitor Group has filed for bankruptcy, and is being acquired by Delloitte . The…
An intriguing graph was posted on Twitter the other day: Now we understand the argument, and it's a good one: As the population ages, there will be more long-term illness,…
In researching our latest project, we came across some startling statistics. A report published by the Crohn's and Colotis Foundation of Canada noted: This landmark document revealed that over 200,000…
Pharmaceutical outsourcing to CROs is certainly nothing new. However, this week we learned that pharmaceutical giant Lilly and AMRI signed an interesting insourcing / outsourcing agreement. In this deal, AMRI…